Recurrent Group 3 Medulloblastoma: Clinical Trials

1 recruiting. 1 Phase 1.

By phase and status

Phase	Trials	Status
Phase 1	1	Recruiting 1

Follow Recurrent Group 3 Medulloblastoma: new trials by email Literature Review of Recurrent Group 3 Medulloblastoma trials Research Report on Recurrent Group 3 Medulloblastoma

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Adoptive T Cell Therapy, DC Vaccines, and Hematopoietic Stem Cells Combined With Immune checkPOINT Blockade in Patients With Medulloblastoma TTRNA-DC vaccines with GM-CSF, TTRNA-xALT, Td vaccine - Recurrent Group 3 Medulloblastoma, Recurrent Group 4 (Non-SHH/Non-WNT) Medulloblastoma	Phase 1	Recruiting	University of Florida	12	2025-05-05	2026-08-07

Narrower conditions

Medulloblastoma (1)

Broader conditions

Glioma (1)  ·  Neoplasms (1)  ·  Neoplasms by Histologic Type (1)  ·  Neoplasms, Germ Cell and Embryonal (1)  ·  Neoplasms, Glandular and Epithelial (1)  ·  Neoplasms, Nerve Tissue (1)  ·  Neoplasms, Neuroepithelial (1)  ·  Neuroectodermal Tumors (1)  ·  Neuroectodermal Tumors, Primitive (1)

Interventions

Diphtheria-Tetanus Vaccine (1)  ·  Granulocyte-Macrophage Colony-Stimulating Factor (1)  ·  pembrolizumab (1)

Sponsors

University of Florida (1)

Countries

United States (1)

Top investigators

Duane Mitchell, MD, PhD (1)  ·  John Ligon, MD (1)